Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Melih Ozel is active.

Publication


Featured researches published by A. Melih Ozel.


Journal of Gastroenterology and Hepatology | 2004

Leptin levels in the acute stage of ulcerative colitis

Ahmet Tüzün; Ahmet Uygun; Zeki Yesilova; A. Melih Ozel; Ahmet Erdil; Halil Yaman; Sait Bagci; Mustafa Gulsen; Necmettin Karaeren; Kemal Dagalp

Background and Aims:  Leptin, a recently discovered protein, acts as a hormonal feedback signal in regulating adipose tissue mass via hypothalamic mechanisms. Inflammatory bowel disease is often associated with anorexia and weight loss. The aim of the present study was to investigate serum leptin levels during the time course of the acute phase of ulcerative colitis (UC) and to evaluate whether leptin leads to anorexia and bodyweight loss in these patients.


Journal of Gastroenterology and Hepatology | 2007

Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy

Ahmet Uygun; A. Melih Ozel; Oguzhan Yildiz; Murat Aslan; Zeki Yesilova; Ahmet Erdil; Sait Bagci; Ömer Günhan

Background and Aim:  Many studies have reported poor results with standard first‐line treatment for Helicobacter pylori. Second‐line regimens that may overcome bacterial resistance can minimize side‐effects and optimize compliance. The aim of this study was to evaluate the efficacy of proton pump inhibitor (PPI) and bismuth subcitrate‐based quadruple therapy, after failure of a PPI plus clarithromycin and amoxicillin as first‐line therapy.


Southern Medical Journal | 2005

Effect of N-acetyl cysteine on Helicobacter pylori.

Ahmet Kemal Gurbuz; A. Melih Ozel; Ramazan Öztürk; Sukru Yildirim; Yusuf Yazgan; Levent Demirturk

Background: Use of mucolytic agents that result in reduced mucous viscosity of the gastric mucous has been suggested to have an additive effect in curing Helicobacter pylori infection. Methods: Seventy H pylori–positive patients were given either eradication treatment consisting of 500 mg clarithromycin bid and 30 mg lansoprazole bid for 10 days plus 10 mL (400 mg) N-acetyl cysteine (NAC) liquid tid (AC group) or eradication treatment only (control group). The results were compared 1 month after the completion of the treatment. Results: Fifty-eight patients were available for statistical analysis. Of the 28 patients in the AC group, 14 (50.0%) eradicated the infection after treatment, whereas only 7 of 30 (23.3%) patients in the control group had negative results. The difference between the AC group and the control group was statistically significant (P = 0.034). In both groups, there was no difference in the number of smokers and in the eradication rates between smokers and nonsmokers. Eradication treatment with or without NAC caused no significant side effects in either group. Conclusions: Our findings suggest that NAC has an additive effect on the eradication rates of H pylori obtained with dual therapy with lansoprazole and clarithromycin. NAC does not have any known activity against H pylori, but it may improve the delivery of antibiotics at the site of infection due to its ability to reduce the thickness of the mucus.


Helicobacter | 2001

CagA status in dyspeptic patients with and without peptic ulcer disease in Turkey: association with histopathologic findings.

Levent Demirturk; A. Melih Ozel; Yusuf Yazgan; Emrullah Solmazgul; Şükrü Yildirim; Mustafa Gültepe; A. Kemal Gürbüz

CagA seropositivity is closely associated with that of vacuolating cytotoxin (VacA). Helicobacter pylori strains positive for both VacA and CagA were reported to be strongly associated with peptic ulcer disease. Different results reporting that cagA gene is not associated with more serious diseases, lowers the importance of CagA protein as a marker. In this study, CagA seropositivity is examined in Turkish peptic ulcer and nonulcer dyspepsia patients; histopathologic scores of CagA (+) and CagA (−) groups were compared.


Southern Medical Journal | 2004

Gallbladder and gastric motility in patients with idiopathic slow-transit constipation.

Alp Günay; A. Kemal Gürbüz; Yavuz Narin; A. Melih Ozel; Yusuf Yazgan

Objective Idiopathic slow-transit constipation (STC) has been suggested to be a pangastrointestinal motility disorder. We investigated scintigraphically whether motility in the gallbladder and stomach was impaired in slow-transit constipation. Methods Twenty-four patients with STC were studied. Colon transit time, gallbladder motility, and solid-phase gastric emptying were measured by scintigraphy. Results Gallbladder dysmotility was observed in 8 of 18 (44.4%) patients. Mean gallbladder ejection fraction was 41.6 ± 13.6% (range, 16.3–67.0%). Gastric emptying was delayed in 9 of 18 (50%) patients. Mean solid-phase gastric half-emptying time was 75 minutes. STC may be associated with impaired function of other gastrointestinal organs. Approximately half of patients with STC presented gallbladder or gastric dysmotility. Conclusion STC may not be a pure colonic abnormality; it may be a component of a pangastrointestinal tract motility disorder involving several organs.


Journal of Gastroenterology and Hepatology | 2003

Value of regional cerebral blood flow in the evaluation of chronic liver disease and subclinical hepatic encephalopathy

Yusuf Yazgan; Yavuz Narin; Levent Demirturk; Mehmet Saracoglu; Mustafa Ercan; Nevzat Akyatan; Nagehan Dalkanat; A. Melih Ozel; Mesut Cetin

Aims:  Regional changes in cerebral blood flow in patients with chronic hepatitis, cirrhosis and subclinical hepatic encephalopathy were investigated in the present study using single photon emission computed tomography (SPECT).


Helicobacter | 2012

Efficacy of a Modified Sequential Therapy Including Bismuth Subcitrate as First-Line Therapy to Eradicate Helicobacter pylori in a Turkish Population

Ahmet Uygun; A. Melih Ozel; Bulent Sivri; Zulfikar Polat; Halil Genc; Yusuf Serdar Sakin; Gurkan Celebi; Oya Uygur-Bayramicli; Cemal Nuri Erçin; Abdurrahman Kadayifci; Ozdes Emer; Armagan Gunal; Sait Bagci

Eradication rates of Helicobacter pylori with standard triple therapy are not satisfactory. Sequential therapy is an alternative method to overcome this problem.


Renal Failure | 2007

Urinary Glycosaminoglycan Levels as a Marker of Renal Amyloidosis in Patients with Familial Mediterranean Fever

Hakan Nadir; Suat Unver; A. Melih Ozel; Yusuf Yazgan; Mustafa Gültepe; T. Rifki Evrenkaya; Levent Demirturk; Ahmet Kemal Gurbuz

Introduction and aim. Familial Mediterranean Fever (FMF) is an autosomal recessive disease with a defect in the pyrine gene and is manifested with short attacks of inflammatory serositis, fever, and erysipelas-like skin lesions. Secondary amyloidosis is the most serious complication of the disease, in which extracellular deposits of amyloid (an amorphous and eosinophilic protein) are seen in tissues. Glycosaminoglycans are mucopolysaccharide molecules that take place in amyloid deposits with fibrillar links to amyloid. They form glycoproteins by linking to proteins, and their free forms are excreted in the urine in the form of polysaccharides. The aims of this study were to evaluate if the urinary levels of glycosaminoglycans have a predictive value in the diagnosis of amyloidosis secondary to FMF and if these levels are affected by treatment with colchicine. Materials and methods. The study included 55 volunteer patients (age range: 18–36 years) with FMF (15 with amyloidosis) of the same socio-economic circumstances without other concomitant inflammatory, malignant, or chronic diseases, along with 20 healthy subjects as control. Urinary glycosaminoglycan levels were determined twice, once when the patients were on medication and once after they have stopped treatment for two weeks. Results. Initial mean urinary GAG levels were significantly lower in amyloidosis patients. Mean urinary GAG levels determined two weeks after the cessation of colchicine was also significantly lower than controls in both amyloidosis and non-amyloidosis FMF patients. Likewise, in patients with a disease duration longer than ten years, urinary GAG levels were also lower than those with a disease duration of less than three years. Conclusion. Urinary GAG level can have a predictive value for amyloidosis in patients with FMF, and it can also be used as a non-invasive marker for screening the effects of colchicine on fibrillogenesis as well as for the follow-up of the patients.


Gastroenterology | 2014

Su1160 Do Probiotics Improve Eradication Response Rate of Modified First-Line Treatment for Helicobacter pylori?

Hakan Demirci; Ahmet Uygun; A. Melih Ozel; Yusuf Serdar Sakin; Zulfikar Polat; Murat Kantarcioglu; Mustafa Gulsen; Sait Bagci


Gastroenterology | 2013

Mo1008 Role of TWEAK in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Zulfikar Polat; Ahmet Uygun; A. Melih Ozel; Metin Basaranoglu; Fatih Aslan; Mustafa Gulsen; Sait Bagci

Collaboration


Dive into the A. Melih Ozel's collaboration.

Top Co-Authors

Avatar

Yusuf Yazgan

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ahmet Uygun

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar

Sait Bagci

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mustafa Gulsen

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar

Zulfikar Polat

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar

Ahmet Erdil

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yavuz Narin

Military Medical Academy

View shared research outputs
Researchain Logo
Decentralizing Knowledge